ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Consumer Products

Amyris exits vitamin E in deal with DSM

by Melody M. Bomgardner
April 26, 2019 | APPEARED IN VOLUME 97, ISSUE 17

Biobased specialty firm Amyris will wrap up a years-long vitamin E deal by selling its royalty rights to partner DSM for $57 million. Amyris will no longer be in the vitamin E business, but the two firms will continue to work together. In 2017, Amyris sold its plant in Brotas, Brazil, to DSM. Now DSM will produce Amyris’s molecules for markets including flavors and fragrances, skin care, sweeteners, and cannabinoids. That deal will be worth up to $40 million over the next 3 years, Amyris says.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment